Normalisation of tissue factor pathway inhibitor activity after glycaemic control optimisation in type 1 diabetic patients

Thromb Haemost. 2000 Aug;84(2):223-7.

Abstract

Increased plasma concentrations of various markers of endothelial damage have been observed in type I diabetic patients, particularly in those with microangiopathy.

Objective: To evaluate the effect of near-normalisation of glycaemic control on different markers of endothelial injury involved in haemostasis in poorly-controlled type 1 diabetic patients.

Material and methods: TFPI, thrombomodulin (TM), plasminogen activator inhibitor, tissue-type plasminogen activator and von Willebrand factor were measured in 14 poorly-controlled type 1 diabetic patients free of diabetes-related complications (8 men, 6 women; mean age 29.8 +/- 9.9 years) before (baseline) and after 3 months of intensive therapy and in 14 sex-, age- and BMI-matched control subjects.

Results: After a mean follow-up of 107 +/- 49 days (56-210), HbA1c decreased from 11.2 +/- 2.3 to 6.7 +/- 0.7% (p <0.0001). TFPI activity at baseline was higher than in the control group (126.9 +/- 34 vs 92.0 +/- 13%, p <0.005) and decreased after good glycaemic control was achieved (p <0.005), becoming similar to that in the control group (91.0 +/- 16.5%). The TFPI descent correlated with the variations observed in HbA1c (p <0.05; r = 0.54). TM levels at baseline were significantly higher than in the control group (42.3 +/- 9.1 vs 29.00 +/- 10.9; p <0.005) and did not change. The remaining parameters studied were similar between patients and controls and did not change after glycaemic optimisation.

Conclusions: Optimisation of glycaemic control normalises the increased activity of TFPI but not the higher TM levels observed in poorly-controlled type I diabetic patients without chronic complications.

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Analysis of Variance
  • Biomarkers / blood
  • Blood Coagulation Factors / metabolism
  • Blood Glucose / metabolism*
  • Cholesterol, LDL / blood
  • Diabetes Mellitus, Type 1 / blood*
  • Diabetes Mellitus, Type 1 / complications
  • Diabetes Mellitus, Type 1 / therapy
  • Endothelium, Vascular / injuries
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / pathology
  • Female
  • Fibrinolytic Agents / blood
  • Follow-Up Studies
  • Hemostasis
  • Humans
  • Hyperglycemia / blood
  • Hyperglycemia / complications*
  • Hyperglycemia / therapy
  • Lipids / blood
  • Lipoproteins / blood*
  • Lipoproteins / drug effects
  • Male
  • Matched-Pair Analysis
  • Middle Aged
  • Peptide Fragments / blood
  • Prothrombin
  • Thrombomodulin / blood

Substances

  • Biomarkers
  • Blood Coagulation Factors
  • Blood Glucose
  • Cholesterol, LDL
  • Fibrinolytic Agents
  • Lipids
  • Lipoproteins
  • Peptide Fragments
  • Thrombomodulin
  • lipoprotein-associated coagulation inhibitor
  • prothrombin fragment 1.2
  • Prothrombin